76.8 F
New York
Saturday, July 2, 2022

Why Chiasma [NASDAQ: CHMA] Stock is Skyrocketed?

Must read

Shares of Chiasma, Inc. [NASDAQ: CHMA] surged 46.48% during the trading session of Wednesday. Chiasma has disclosed the financial results for the Q1 completed March 31, 2021, and also presented a business update. The firm has also provided business updates. The firm disclosed that its net revenue reached $1.9 million for the sales of MYCAPSSA in the Q1 of 2021.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.

Sponsored

Furthermore, the SG&A expenses for the Q1 of 2021 stood out at $15.7 million while the R&D expenses for the firm for the Q1 of 2021 reached $4.2 million as compared to the $8.1 million for the Q1 of 2021. The firm has reported the net loss for the Q1 of 2021 remained ($30.5) million, or ($0.49) per basic share. While the net loss for the same quarter in the earlier year stood at ($15.4) million, or ($0.36) per basic share.

Shares of CHMA surged 41.90% as it gained +1.19 at the time of writing on Wednesday. The firm has reported the price of $4.03 per share on the trading session of Wednesday. In the past 52-week trading session, the firm’s share went up 57.40% from its 52-weeks low and went down -43.74% from its 52-week of high range. The market cap of firm reached $165.91 million at the time of writing.

Additionally, the firm disclosed its cash position in 2021. Chiasma completed the Q1 2021 with cash, cash equivalents, and marketable securities of $115.0 million, as compared with $135.4 million as of December 31, 2020. Moreover, CHMA revealed it has inked a conclusive merger accord for the buying of the firm by Amryt Pharma plc.

More articles

Latest article

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

Download Free eBook For

The 5 Best Growth Stocks 2022

100% free. stop anytime no spam